Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache

• Status: Not yet recruiting
• Trial end date: 2022-11-15
• Target enrollment: 0
• Participant gender: Female

Summary

Postdural puncture headache (PDPH) is a potential complication after spinal anesthesia caused by traction on pain-sensitive structures from low cerebrospinal fluid pressure (intracranial hypotension) following a leak of cerebrospinal fluid at the puncture site. Symptoms of this condition include a bilateral frontal or occipital headache that is worse in the upright position, along with nausea, neck pain, dizziness, visual changes, tinnitus, hearing loss, or radicular symptoms in the arms.

This study will examine the efficacy of mirtazapine in in the treatment of PDPH after obstetric surgery under spinal anesthesia and compared its efficacy with that of sumatriptan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Mirtazapine; Sumatriptan

Criteria

Inclusion Criteria:

• ASA I and II Patients.

• Patients undergoing obstetric surgeries under spinal anesthesia. and complaining from moderate-to-severe PDPH after 25G spinal needle puncture.

Exclusion Criteria:

• Refusal of the intervention or participation in the study.

• Patient under age of 18 years old.

• Psychiatric illness.

• Patients with a history of ischemic heart disease, pregnancy-induced hypertension, chronic hypertension, cardiac, vascular, liver or renal impairment.

• Patients with a history of migraine.

• Patients with known hypersensitivity to study drugs.

• Patients currently using ergotamine, monoamine oxidase inhibitors, or selective serotonin reuptake inhibitors.